MedTrace Logo

Treatment of Adenoviral Conjunctivitis With SHP640 Compared to Placebo

NCT02998554 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 156

Last updated 2021-06-09

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine if an investigational treatment is effective compared with placebo in the treatment of adults and children with adenoviral conjunctivitis.

Conditions

  • Adenoviral Conjunctivitis

Interventions

DRUG

SHP640

Instill 1 drop of SHP640 (PVP-I 0.6% and Dexamethasone 0.1%) ophthalmic suspension in each eye 4 times daily (QID) (with a minimum of 2 hours between doses) for 7 days.

DRUG

Placebo

Instill 1 drop of placebo ophthalmic solution in each eye QID for 7 days.

Sponsors & Collaborators

  • Shire

    lead INDUSTRY

Principal Investigators

  • Study Director · Takeda

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-03-28
Primary Completion
2019-05-16
Completion
2019-05-16
FDA Drug
Yes

Countries

  • United States
  • Puerto Rico

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02998554 on ClinicalTrials.gov